Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
BMC Urology
Published in: BMC Urology 1/2016

Open Access 01-12-2016 | Research article

The efficacy and safety of silodosin for the treatment of ureteral stones: a systematic review and meta-analysis

Authors: Diandong Yang, Jitao Wu, Hejia Yuan, Yuanshan Cui

Published in: BMC Urology | Issue 1/2016

Login to get access

Abstract

Background

To evaluate the efficacy and safety of silodosin as a medical expulsive therapy for ureteral stones by means of a systematic review and meta-analysis.

Methods

We searched MEDLINE, EMBASE and the Cochrane Controlled Trials Register to identify randomized controlled trials (RCTs) of silodosin in the treatment of ureteral stones. The reference lists of retrieved studies were also investigated.

Results

Six RCTs, including 916 participants and comparing silodosin with controls, were used in the meta-analysis. Silodosin was superior to controls in terms of stone expulsion rate, the primary efficacy end point in all six RCTs (odds ratio [OR] for expulsion 2.16, 95 % confidence interval [CI] 1.62 to 2.86, p <0.00001). Silodosin was also more effective for secondary efficacy end points; the stone expulsion time (standardized mean difference [SMD] −3.66, 95 % CI −6.61 to −0.71; p =0.01) and analgesic requirements (SMD −0.89, 95 % CI −1.19 to −0.60; p < 0.00001) were significantly reduced compared with those of controls. Other than the incidence of abnormal ejaculation, which was higher in the silodosin groups (OR 2.84, 95 % CI 1.56 to 5.16, p =0.0006), few adverse effects were observed.

Conclusion

This meta-analysis indicates silodosin is an effective and safe treatment option for ureteral stones with a low occurrence of side effects.
Literature
1.
Stefanos PJ, Michael C. Trussa, Treatment strategies of ureteral stones. EAU-EBU Up-date Series. 2006;4:184–90.CrossRef
2.
Sakhaee K, Maalouf NM, Sinnott B. Clinical review. Kidney stones 2012: pathogenesis, diagnosis, and management. J Clin Endocrinol Metab. 2012;97:1847–60.CrossRefPubMedPubMedCentral
3.
Bihl G, Meyers A. Recurrent renal stone disease-advances in pathogenesis and clinical management. Lancet. 2011;358:651–6.CrossRef
4.
Dellabella M, Milanese G, Muzzonigro G. Randomized trial of the efficacy of tamsulosin, nifedipine and phloroglucinol in medicalexpulsive therapy for distal ureteral calculi. J Urol. 2005;174:167–72.CrossRefPubMed
5.
Borghi L, Meschi T, Amato F, Novarini A, Giannini A, Quarantelli C, et al. Nifedipine and methylprednisolone in facilitating ureteral stone passage: a randomized, double-blind, placebo-controlled study. J Urol. 1994;152:1095–8.CrossRefPubMed
6.
Porpiglia F, Destefanis P, Fiori C, Fontana D. Effectiveness of nifedipine and deflazacort in the management of distal ureter stones. Urology. 2000;56:579–82.CrossRefPubMed
7.
Tzortzis V, Mamoulakis C, Rioja J, Gravas S, Michel MC, de la Rosette JJ. Medical expulsive therapy for distal ureteral stones. Drugs. 2009;69:677–92.CrossRefPubMed
8.
Tatemichi S, Kobayashi K, Maezawa A, Kobayashi M, Yamazaki Y, Shibata N. α1-Adenoceptor subtype selectivity and organ specificity of silodosin (KMD-3213). Yakugaku Zasshi. 2006;126:209–16.CrossRefPubMed
9.
Jadad AR. Randomised controlled trials. London: BMJ Publishing Group; 1998.
10.
11.
12.
13.
Itoh Y, Okada A, Yasui T, Hamamoto S, Hirose M, Kojima Y. Efficacy of selective α1A adrenoceptor antagonist silodosin in the medical expulsive therapy for ureteral stones. Int J Urol. 2011;18:672–4.PubMed
14.
Tsuzaka Y, Matsushima H, Kaneko T, Yamaguchi T, Homma Y. Naftopidil vs silodosin in medical expulsive therapy for ureteral stones: a randomized controlled study in Japanese male patients. Int J Urol. 2011;18:792–5.CrossRefPubMed
15.
Gupta S, Lodh B, Singh AK, Somarendra K, Meitei KS, Singh SR. Comparing the efficacy of tamsulosin and silodosin in the medical expulsion therapy for ureteral calculi. J Clin Diagn Res. 2013;7:1672–4.PubMedPubMedCentral
16.
Dell’Atti L. Silodosin versus Tamsulosin as medical expulsive therapy for distal ureteral stones: a prospective randomized study. Urologia. 2014;82:54–7.CrossRefPubMed
17.
Sur RL, Shore N, L’Esperance J, Knudsen B, Gupta M, Olsen S, et al. Silodosin to Facilitate Passage of Ureteral Stones: A Multi-institutional, Randomized, Double-blinded, Placebo-controlled Trial. Eur Urol. 2014;67:959–64.CrossRefPubMed
18.
Kumar S, Jayant K, Agrawal MM, Singh SK, Agrawal S, Parmar KM. Role of tamsulosin, tadalafil, and silodosin as the medical expulsive therapy in lower ureteric stone: a randomized trial (a pilot study). Urology. 2015;85:59–63.CrossRefPubMed
19.
Sun X, He L, Ge W, Lv J. Efficacy of selective alpha1D-blocker naftopidil as medical expulsive therapy for distal ureteral stones. J Urol. 2009;181:1716–20.CrossRefPubMed
20.
21.
De SM, Autorino R, Di LG, Damiano R, Giordano D, Cosentino L. Medical expulsive treatment of distal-ureteral stones using tamsulosin: a single-center experience. J Endourol. 2006;20:12–6.CrossRef
22.
Sasaki S, Tomiyama Y, Kobayashi S, Kojima Y, Kubota Y, Kohri K. Characterization of α1-adrenoceptor subtypes mediating contraction in human isolated ureters. Urology. 2011;77:762.e13-17.CrossRef
23.
Kobayashi S, Tomiyama Y, Hoyano Y, Yamazaki Y, Kusama H, Itoh Y. Gene expressions and mechanical functions of α1-adrenoceptor subtypes in mouseureter. World J Urol. 2009;27:775–80.CrossRefPubMed
24.
Preminger GM, Tiselius HG, Assimos DG, Alken P, Buck C, Gallucci M, Knoll T, Lingeman JE, Nakada SY, Pearle MS, et al. 2007 guideline for the management of ureteral calculi. J Urol. 2007;178(6):2418-34.
25.
Cui Y, Zong H, Zhang Y. The efficacy and safety of silodosin in treating BPH: a systematic review and meta-analysis. Int Urol Nephrol. 2013;44:1601–9.
26.
Montorsi F. Profile of Silodosin. Eur Urol Suppl. 2010;491–495.
27.
Imperatore V, Fusco F, Creta M, Di Meo S, Buonopane R, Longo N, et al. Medical expulsive therapy for distal ureteric stones: tamsulosin versus silodosin. Arch Ital Urol Androl. 2014;86:103–7.CrossRefPubMed
Metadata
Title
The efficacy and safety of silodosin for the treatment of ureteral stones: a systematic review and meta-analysis
Authors
Diandong Yang
Jitao Wu
Hejia Yuan
Yuanshan Cui
Publication date
01-12-2016
Publisher
BioMed Central
Published in
BMC Urology / Issue 1/2016
Electronic ISSN: 1471-2490
DOI
https://doi.org/10.1186/s12894-016-0141-y

Other articles of this Issue 1/2016

BMC Urology 1/2016 Go to the issue

Case report

Case report: Xanthogranulomutous pyelonephritis presenting as “Wilms’ tumor”

Research article

An observational study of the use of beclomethasone dipropionate suppositories in the treatment of lower urinary tract inflammation in men

Research article

Frequent mismatch-repair defects link prostate cancer to Lynch syndrome

Research article

Surgical treatment of Peyronie’s disease with autologous tunica vaginalis of testis

Case report

An ectopic adreocortical adenoma of the renal sinus: a case report and literature review

Research article

A novel stepwise micro-TESE approach in non obstructive azoospermia